-
South African voters report smoother local election but declining IEC trust
-
UN members approve talks on treaty protocol against environmental crime
-
Dolly Parton museum and Nashville hotel open after singer’s death
-
Family-run West Sussex beach café prepares for first winter season
-
George and Amal Clooney attend New York political-comedy reading
-
CT scans reveal health and burial clues from Egypt’s Braided Lady mummy
-
British buyers pay substantial premiums for period-home appearance
-
Oxford faces complaints over lecturer’s classroom attire
-
Thomas Markle released to house arrest after child-abuse-image charge
-
Kyren Wilson and John Higgins reach International Championship snooker final
-
Dawn of War 4 developers chose Adeptus Mechanicus for tactical variety
-
New Zealand and Tonga meet for place in Rugby League World Cup final
-
Italy face unbeaten South Africa in Turin Nations Championship match
-
Reports of unsafe AI-toy responses renew calls for child-safety rules
-
ChatGPT interactive interface feature tested across six custom tools
-
Juneau food network combines difficult supply routes with deep sharing traditions
-
Freshways milk-price cut deepens pressure on UK dairy farms
-
India climbs green-transition ranking after first emissions decline in 25 years
-
Labour and National remain virtually tied as New Zealand vote count advances
-
Trump names Stephen Miller as White House chief of staff after midterm losses
-
The Good Daughter adapts Karin Slaughter thriller with Rose Byrne and Meghann Fahy
-
Restored Albanian tower houses anchor new rural tourism trail
-
Heavy-lift drone evacuates wounded Ukrainian soldier from frontline kill zone
-
Sonia Gandhi reflects on family tragedy and reluctant political career
-
Morrison says West Brom recovered after pressure from successive derby losses
-
Pope Leo begins three-country South American tour in Uruguay
-
Britain considers 2027 state visit for Ukraine’s Zelensky
-
Khawaja says entire Australia camp knew of 2018 ball-tampering plan
-
Arizona Democrats Secure Historic Trifecta with New Legislative Leadership
-
Anna Miltina Confronted with Racism Allegations on ProSieben Show
-
Carney Welcomes U.S. Trade Reversal After Democratic Midterm Victory
-
Microsoft Xbox App Update for PC Promises 60% Faster Startup
-
Armenian FM Discusses EU Accountability for Palestinian Rights in Madrid
-
California Humanities Honors Valdez and Burroughs for Courageous Leadership
-
Trump and Vance Pursue Secret Diplomacy with Iran Amid Military Pressure
-
Friedmann and Kühner Analyze Bundesliga's Best Shot and Frankfurt's Goalkeeper Crisis
-
Classic Car Values Surge: De Tomaso Vallelunga Leads 190% Gain
-
Honoka‘a Dragons Face Hawaii Prep in BIIF Division II Championship
-
Microsoft Ends Oracle AI Computing Rental Deal Amid Cloud Strategy Shift
Court to weigh bid to ban abortion pill in US
A Texas courtroom will be the latest battleground in the national fight over abortion rights when a judge hears arguments Wednesday over the legality of a widely-used abortion pill.
Galvanized after the US Supreme Court ended the nationwide right to abortion last June, anti-abortion forces have since targeted the federally-approved drug mifepristone in their effort to win a total ban on the practice.
US District Court Judge Matthew Kacsmaryk announced Monday the hearing in Amarillo, Texas on a lawsuit alleging the US Food and Drug Administration (FDA) should never have approved the "dangerous" prescription pill in 2000.
One component of a two-drug regimen used for medication abortion, mifepristone has been used by an estimated 5.6 million women to terminate pregnancies since its approval, according to the FDA.
It can be used in the United States up to 10 weeks of pregnancy.
The pro-abortion rights Guttmacher Institute estimates that more than half of all abortions involve the use of the drug.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying the approval of mifepristone "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with its use.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
With abortion opponents now focused on curtailing access to mifepristone, the treatment has already been halted in some 15 states which have banned all abortion since the 2022 Supreme Court decision.
The Texas suit seeks to block it nationally by overturning the FDA's approval of the drug.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
- Conservative Christian -
Judge Kacsmaryk was targeted by the plaintiffs to hear the case due to his deep conservative Christian beliefs and previous anti-abortion stance.
He had been expected since February 24 to issue a ruling in the case, which asks him to suspend the FDA's approval of the drug while the lawsuit proceeds.
Apparently fearing protesters descending on the courthouse in Amarillo, Kacsmaryk originally sought to keep the hearing secret until the last minute, but it leaked to media.
If he does order the suspension, it could leave pregnant women with the alternative of using only misoprostol, the second pill in the medication abortion treatment.
But using misoprostol alone is more physically traumatic than the two-pill procedure, and some fear doctors might be unwilling to prescribe it alone.
If mifepristone is banned, "access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
"The decision would be unprecedented, as you know, and devastating to women. And we may find ourselves in uncharted territory," White House spokeswoman Karine Jean-Pierre told reporters last week.
"We're closely working with the Justice Department and (the Department of Health and Human Services) on this, on how to be prepared for any range of outcomes," she added.
M.Ouellet--BTB